- Home
- NTRA vs EPAM Comparison
NTRA vs EPAM Comparison
Compare NTRA & EPAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- EPAM
- Stock Information
- Founded
- NTRA 2003
- EPAM 1993
- Country
- NTRA United States
- EPAM United States
- Employees
- NTRA N/A
- EPAM N/A
- Industry
- NTRA Medical Specialities
- EPAM EDP Services
- Sector
- NTRA Health Care
- EPAM Technology
- Exchange
- NTRA Nasdaq
- EPAM Nasdaq
- Market Cap
- NTRA 13.7B
- EPAM 11.5B
- IPO Year
- NTRA 2015
- EPAM 2012
- Fundamental
- Price
- NTRA $129.95
- EPAM $204.89
- Analyst Decision
- NTRA Strong Buy
- EPAM Buy
- Analyst Count
- NTRA 15
- EPAM 20
- Target Price
- NTRA $123.64
- EPAM $257.53
- AVG Volume (30 Days)
- NTRA 1.2M
- EPAM 524.5K
- Earning Date
- NTRA 11-06-2024
- EPAM 10-31-2024
- Dividend Yield
- NTRA N/A
- EPAM N/A
- EPS Growth
- NTRA N/A
- EPAM N/A
- EPS
- NTRA N/A
- EPAM 6.98
- Revenue
- NTRA $1,360,503,000.00
- EPAM $4,621,455,000.00
- Revenue This Year
- NTRA $42.99
- EPAM $0.24
- Revenue Next Year
- NTRA $13.11
- EPAM $4.85
- P/E Ratio
- NTRA N/A
- EPAM $28.93
- Revenue Growth
- NTRA 46.13
- EPAM N/A
- 52 Week Low
- NTRA $36.90
- EPAM $169.43
- 52 Week High
- NTRA $128.28
- EPAM $317.50
- Technical
- Relative Strength Index (RSI)
- NTRA 66.43
- EPAM 51.36
- Support Level
- NTRA $114.62
- EPAM $201.49
- Resistance Level
- NTRA $118.52
- EPAM $205.42
- Average True Range (ATR)
- NTRA 4.62
- EPAM 5.25
- MACD
- NTRA 0.87
- EPAM 0.16
- Stochastic Oscillator
- NTRA 99.77
- EPAM 52.62
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenues. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.